CSL Expands Clazakizumab Strategy Through Strategic Licensing with Lilly
CSL Limited (ASX: CSL) has entered into a sole licensing arrangement with Eli Lilly and Company to advance the development and global rollout of clazakizumab, a monoclonal antibody that targets interleukin-6 (IL-6). As part of the arrangement, CSL will maintain sole rights to progress and market the treatment for reducing cardiovascular risk in patients suffering from end-stage kidney disease (ESKD). Meanwhile, Lilly will lead efforts related to global development, regulatory clearances, and commercialization across other potential therapeutic uses.
Clazakizumab was initially created by Vitaeris and later brought into CSL’s portfolio in 2020. The therapy works by blocking interleukin-6 (IL-6), a signaling protein that plays a central role in persistent inflammation and is linked to a range of vascular and immune-related disorders. CSL is currently advancing the Phase 3 POSIBIL6ESKD clinical trial, which is assessing the drug’s safety and efficacy in dialysis patients at elevated risk of major cardiovascular events. The partnership includes a US$100 million upfront payment to CSL, along with potential milestone payments and royalties tied to future clinical, regulatory, and commercial achievements.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
CSL Expands Clazakizumab Strategy Through Strategic Licensing with Lilly
CSL Limited (ASX: CSL) has entered into a sole licensing arrangement with Eli Lilly and Company to advance the development and global rollout of clazakizumab, a monoclonal antibody that targets interleukin-6 (IL-6). As part of the arrangement, CSL will maintain sole rights to progress and market the treatment for reducing cardiovascular risk in patients suffering from end-stage kidney disease (ESKD). Meanwhile, Lilly will lead efforts related to global development, regulatory clearances, and commercialization across other potential therapeutic uses.
Clazakizumab was initially created by Vitaeris and later brought into CSL’s portfolio in 2020. The therapy works by blocking interleukin-6 (IL-6), a signaling protein that plays a central role in persistent inflammation and is linked to a range of vascular and immune-related disorders. CSL is currently advancing the Phase 3 POSIBIL6ESKD clinical trial, which is assessing the drug’s safety and efficacy in dialysis patients at elevated risk of major cardiovascular events. The partnership includes a US$100 million upfront payment to CSL, along with potential milestone payments and royalties tied to future clinical, regulatory, and commercial achievements.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au